bioAffinity Technologies: CyPath® Lung detects Stage 1A tumor missed by PET scan, bronchoscopies

bioAffinity Technologies, Inc.

CyPath® Lung identified a Stage 1A neuroendocrine tumor after PET scan, bronchoscopies and serum tumor marker suggested non-cancerous inflammation.
Patient was an 80-year-old former smoker with a 13mm nodule; CyPath® Lung returned a score of 0.72 indicating likely cancer.
Based on CyPath® Lung result, patient underwent robotic wedge resection in June 2025; pathology confirmed Stage 1A neuroendocrine tumor.
CyPath® Lung has 92% sensitivity, 87% specificity and 88% accuracy for lung cancer in high-risk patients with small nodules (<20mm).

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.